Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Cosmo Pharmaceuticals N.V.
  6. News
  7. Summary
    COPN   NL0011832936

COSMO PHARMACEUTICALS N.V.

(COPN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

EQS-Adhoc: Cosmo Pharmaceuticals Announces Cassiopea SpA's Signing of License and Supply Agreements for Winlevi(R) in US and Canada

07/26/2021 | 01:02am EDT
EQS Group-Ad-hoc: Cosmo Pharmaceuticals N.V. / Key word(s): Agreement/Alliance 
Cosmo Pharmaceuticals Announces Cassiopea SpA's Signing of License and Supply Agreements for Winlevi(R) in US and 
Canada 
26-Jul-2021 / 06:01 GMT/BST 
Release of an ad hoc announcement pursuant to Art. 53 LR 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Ad hoc announcement pursuant to Art. 53 LR 
Dublin, Ireland - 26 July 2021: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) announced today that Cassiopea SpA 
(SIX: SKIN), a company in which it holds 46.56% of the ordinary shares, has signed license and supply agreements with 
Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, 'Sun Pharma') for 
Winlevi^TM (clascoterone cream 1%) for the US and Canada. 
Winlevi(R) is approved by the United States Food & Drug Administration (FDA) as a novel drug for the topical treatment 
of acne in patients 12 years and older. 
Under the terms of the agreements, Sun Pharma will have the exclusive right to commercialize Winlevi(R) in the United 
States and Canada and Cassiopea will be the exclusive supplier of the product. Cassiopea will receive an upfront 
payment of USUSD 45 million, potential commercial milestones totalling up to USUSD 190 million and customary double-digit 
royalties. The agreements will close upon the expiration of the HSR waiting period. 
Winlevi(R) is expected to be available in the US in Q4 2021. 
Alessandro Della Chà, CEO of Cosmo, said: 'Cassiopea has explored many options over the past several months, and we are 
very pleased that it has finally partnered with Sun Pharma to make Winlevi^TM widely available in the US and Canada. 
This transaction significantly transforms Cassiopea, which will be expecting substantial revenues for the foreseeable 
future and will be in a position to progress the development of its pipeline without the need to raise additional 
equity.' 
Calendar 
Half-year Report 2021                                July 30, 2021 
Commerzbank ODDO BHF Conference                      August 31, 2021 
Wells Fargo Healthcare Conference                    September 9 - 10, 2021 
Investora Conference, Zurich                         September 15 - 16, 2021 
Jefferies London Global Healthcare Conference        November 16 - 18, 2021 
Credit Suisse Swiss Equity Forum Switzerland, Zurich November 16 - 19, 2021 

About Cosmo Pharmaceuticals Cosmo is a specialty pharmaceutical company focused on developing and commercialising products to treat selected gastrointestinal disorders and improve endoscopy quality measures through aiding the detection of colonic lesions. Cosmo has also developed medical devices for endoscopy and has a partnership with Medtronic for the global distribution of GI Genius(TM) its artificial intelligence device that uses artificial intelligence to help detect potential signs of colon cancer. Cosmo has licensed Aemcolo(R) to Red Hill Biopharma Ltd. for the US and has licensed Relafalk(R) to Dr. Falk Gmbh for the EU and other countries. For additional information on Cosmo and its products please visit the Company's website: www.cosmopharma.com

Contact Niall Donnelly, CFO & Head of Investor Relations Cosmo Pharmaceuticals N.V. Tel: +353 1 817 03 70 ndonnelly@cosmopharma.com ----------------------------------------------------------------------------------------------------------------------- End of ad hoc announcement -----------------------------------------------------------------------------------------------------------------------

Language:     English 
Company:      Cosmo Pharmaceuticals N.V. 
              Riverside 2, Sir John Rogerson's 
              Dublin 2 Dublin 
              Ireland 
Phone:        + 353 1 817 0370 
E-mail:       info@cosmopharma.com 
Internet:     https://www.cosmopharma.com/ 
ISIN:         NL0011832936 
Listed:       SIX Swiss Exchange 
EQS News ID:  1221480 
 
End of Announcement EQS Group News Service 
=------------ 

1221480 26-Jul-2021 GMT/BST

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1221480&application_name=news 
 

(END) Dow Jones Newswires

July 26, 2021 01:01 ET (05:01 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
COSMO PHARMACEUTICALS N.V. 1.60% 82.5 Delayed Quote.-2.94%
DJ INDUSTRIAL -0.48% 34584.88 Delayed Quote.13.54%
MEDTRONIC PLC -0.93% 129.7 Delayed Quote.10.72%
SUN PHARMACEUTICAL INDUSTRIES LTD. -1.43% 769.9 Delayed Quote.29.97%
WELLS FARGO & COMPANY 0.41% 46.47 Delayed Quote.53.98%
All news about COSMO PHARMACEUTICALS N.V.
07/30COSMO PHARMACEUTICALS N : Logs Widened H1 Loss On Higher Expenses
MT
07/30EQS-ADHOC : Cosmo Half-Year Report 2021
DJ
07/30Cosmo Pharmaceuticals N.V. Reports Earnings Results for the Half Year Ended J..
CI
07/29EQS-ADHOC : Cassiopea Announces Results for First Half of 2021
DJ
07/26CASSIOPEA S P A : Enters License, Supply Deals for Acne Treatment in North Ameri..
MT
07/26EQS-ADHOC : Cosmo Pharmaceuticals Announces Cassiopea SpA's Signing of License a..
DJ
05/28COSMO PHARMACEUTICALS N : ' Shareholders approve all Agenda Items at Annual Gene..
EQ
05/28EQS-ADHOC : Cosmo Pharmaceuticals' Shareholders approve all Agenda Items at Annu..
DJ
05/10COSMO PHARMACEUTICALS N : announces a change in its board of directors
EQ
05/10Cosmo Pharmaceuticals N.V. Announces Resignation of Hans Christoph Tanner as ..
CI
More news
Analyst Recommendations on COSMO PHARMACEUTICALS N.V.
More recommendations
Financials
Sales 2021 60,8 M 71,2 M 71,2 M
Net income 2021 5,22 M 6,12 M 6,12 M
Net cash 2021 42,1 M 49,4 M 49,4 M
P/E ratio 2021 214x
Yield 2021 -
Capitalization 1 081 M 1 270 M 1 268 M
EV / Sales 2021 17,1x
EV / Sales 2022 13,4x
Nbr of Employees 276
Free-Float 45,1%
Chart COSMO PHARMACEUTICALS N.V.
Duration : Period :
Cosmo Pharmaceuticals N.V. Technical Analysis Chart | COPN | NL0011832936 | MarketScreener
Technical analysis trends COSMO PHARMACEUTICALS N.V.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 75,43 €
Average target price 97,09 €
Spread / Average Target 28,7%
EPS Revisions
Managers and Directors
Niall Donnelly Chief Financial Officer & Head-Investor Relations
Mauro Severino Ajani Executive Chairman
Davide Malavasi Director-Qualified Person & Technical
Stefano Selva Chief Scientific Officer
H. Jurgen Lenz Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
COSMO PHARMACEUTICALS N.V.-2.94%1 270
JOHNSON & JOHNSON4.68%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.20.81%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY36.28%208 604